NCT05683977 2026-02-24
ARSENAL
AstraZeneca
Active not recruiting
Clinical Trials
7 trialsNCT06826677 2025-06-24
ARAL
AstraZeneca
Completed
NCT04667312 2023-10-02
CODAK
AstraZeneca
Completed
NCT04364776 2023-09-28
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Fondazione IRCCS Policlinico San Matteo di Pavia
Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04285866 2022-06-07
S-REAL
Fundación GECP
Completed
NCT04672759 2020-12-17
A Real-world Study of Durvalumab for Lung Cancer in China
Peking Union Medical College Hospital
Unknown